Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

SEP 17, 2014 - Zacks Investment Research

A Must Read - Share

UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog

UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.

Tags: UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog,  Amgen Latest News

SEP 12, 2014 - Yahoo! News

A Must Read - Share

Biotech shares drop, Amarin plunges 20 percent

By Ryan Vlastelica NEW YORK (Reuters) - Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector. The Nasdaq Biotech index is down 0.9 percent, falling for a seventh session out of the past nine. Biotechs are a frequent target for profit-taking, as many investors view the group - which ...

Tags: Biotech shares drop, Amarin plunges 20 percent,  Amgen Latest News

SEP 11, 2014 - TheStreet

A Must Read - Share

Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs

NEW YORK (TheStreet) -- Investing in biotech is not for the faint of heart. Stocks in the sector are volatile, depending on positive or negative reports from the U.S. Food and Drug Administration on drugs in the companies' pipelines. Each of six biotech stocks profiled here have market capitalizations above $30 billion and have solid year-to-date gains led by Gilead ...

Tags: Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs,  Amgen Latest News

SEP 10, 2014 - TheStreet

A Must Read - Share

Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager

Marathon Oil is a restructuring story and is cheap compared to fellow North American E&P players, said Thomas Forester, portfolio manager for the Forester Value Fund.

Tags: Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager,  Amgen Latest News

SEP 04, 2014 - Zacks Investment Research

A Must Read - Share

Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog

Earlier this week, Amgen Inc. (AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its PCSK9 inhibitor, evolocumab (AMG 145) for the treatment of high cholesterol.

Tags: Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog,  Amgen Latest News